A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Clinical trial NCT07421167 · RECRUITING

Trial details

NCT number: NCT07421167
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)

Start date: 2026-08-04
Primary completion: 2028-05-09
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.